Infex Therapeutics Ltd. has divulged nonstructural protein 3 (nsp3, PL-PRO) macrodomain (Mac1) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines.
Researchers from the University of Queensland have published preclinical data on the novel glycopeptide antibiotic MCC-5145, being developed for the treatment of gram-positive bacterial infections.
Antimicrobial peptides (AMPs) are a type of active peptide produced by the organism that are important host-defense factors, with broad-spectrum antibacterial properties, as well as significant properties such as antifungal and antiviral activity and immune regulation, among others.
Preclinical research led by the University Hospital Würzburg in Germany shows early promise for chimeric antigen receptor (CAR) T-cell therapies to treat invasive pulmonary aspergillosis, a serious fungal infection with limited current treatment options.
The Nobel Prize in Physiology or Medicine 2022 was awarded to Svante Pääbo today "for his discoveries concerning the genomes of extinct hominins and human evolution." Pääbo, who is currently the director of the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, and his colleagues overcame extreme technical challenges to sequence the DNA of ancient hominids – because after tens of thousands of years, there is no such thing as aging well for DNA.
Maxwell Biosciences Inc. has announced data on the utility of its Claromer drug discovery platform for the treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of preclinical in vitro and in vivo studies.
To jumpstart the development of much-needed antibiotics, the European Federation of Pharmaceutical Industries and Associations (EFPIA) released a new report Sept. 28 demonstrating the economic benefit of granting additional exclusivity for another drug as a way of incentivizing antibiotic R&D.
Moleculin Biotech Inc.'s WP-1096 molecule is set to be evaluated in animal studies through the preclinical services offered by the National Institute of Allergy and Infectious Diseases (NIAID).
The race to become the first microbiome-based therapy to reach the market continues between two companies. A positive view by the U.S. FDA’s Vaccines and Related Biological Products Advisory Committee on Sept. 22 for RBX-2660 in preventing recurrent Clostridium difficile infection kept Ferring Pharmaceuticals Inc.’s microbiota-based live biotherapeutic moving forward.
RSS
